Italy: anti-diabetes drugs revenue growth 2019-2029

The revenue change in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in Italy was forecast to continuously decrease between 2024 and 2029 by in total 3.3 percentage points. According to this forecast, in 2029, the indicator will have decreased for the sixth consecutive year to 5.59 percent.

Find further information concerning the revenue in the 'Vaccines' segment of the pharmaceuticals market in Argentina and the revenue change in the pharmaceuticals market in Italy.

The Statista Market Insights cover a broad range of additional markets.

Revenue growth of anti-diabetes drugs in Italy between 2019 and 2029

Characteristic	Revenue growth
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Citation formats